

4DMedical and Philips sign Teaming Agreement

22 January 2024

Highlights

- 4DMedical and Philips formalise MoU with Teaming Agreement for commercialisation expansion of XV Technology® within the U.S. Department of Veterans Affairs (VA)
- Philips is a leading global healthcare company and one of the VA's most important partners; 50% of VA clinics use Philips imaging informatics systems
- Philips and 4DMedical will now combine their efforts to seek contracts from the VA to offer 4D lung imaging as a critical solution for Veterans exposed to burn pits and other airborne hazards while on deployment

Melbourne, Australia, 22 January 2024: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, "4DMedical", or the "Company") today announces that it has signed a commercial agreement ("Teaming Agreement") with Koninklijke Philips N.V. (NYSE: PHG or "Philips"), a leading global healthcare company, to establish a strategic collaboration to advance solutions to evaluate Veterans with deployment-related respiratory disease (DRRD), interstitial lung disease (ILD) and other respiratory illnesses in North America.

Addressing the toxic exposures public health crisis with 4DMedical's lung analysis tools

Following the announcement late last year that the companies had entered into a Memorandum of Understanding (MoU) to expand the commercial reach and access for 4DMedical, the signing of this agreement represents a major step forward in the Company's commercialisation strategy, particularly within the VA. Philips and 4D Medical will work together to support the massive need to scale non-invasive lung screening in support of the PACT Act, which extended eligibility for benefits to an additional 4.5 million Veterans. Philips has long-established and significant existing partnerships with both the VA and the Department of Defense (DoD) going back 45 years, deploying 35% of the critical care information systems across the VA, and having Philips imaging solutions in 50% of VA hospitals. Accessing this team of industry experts, with unparalleled relationships in global healthcare, provides an unprecedented opportunity to accelerate 4DMedical's go-to-market activities, particularly in the VA.

Philips' strategic cooperation with 4DMedical focuses on scaling Veteran access to XV Technology®

Philips is a global leader in health care with €18.5 billion (\$30.8 billion) in reported revenues and employs approximately 75,000 staff globally. Philips Healthcare is a leading provider of innovative health technology solutions, with a strong presence in North America, their largest market. They are known for their commitment to improving patient outcomes, enhancing health care delivery, and driving operational efficiency. Philips offers a wide range of products and services, including advanced imaging systems, patient monitoring solutions, and healthcare informatics. Through the combined offering with 4DMedical, Philips intends to grow their market share in their capital equipment sales and service offerings, plus attachment through their PACS portfolio, as they look to better serve the Veteran community.



Establishing a strategic cooperation

The second step in this collaboration is the signing of this Teaming Agreement to advance solutions to evaluate Veterans for deployment-related respiratory disease as part of a broader lung screening initiative. Philips and 4DMedical will jointly focus on offering 4D lung imaging as a critical solution for Veterans exposed to burn pits and other airborne hazards on deployment. Under the terms of the agreement, the 4DMedical and Philips teams will collaborate to develop solutions for toxic exposure and lung screening using 4DMedical software and Philips fluoroscopy and CT systems.

Subsequently, the parties intend to formalise a reseller agreement under which 4DMedical's XV Technology® and Imbio portfolio will be added to Philips' product catalogue and offered as a third-party solution providing access to both software and hardware, to other US-based federal agencies and commercial organisations in North America. The parties will also consider other markets outside of North America for expansion.

4DMedical MD/CEO and Founder Andreas Fouras said:

Starting 2024 by formalising this teaming agreement with Philips is an exceptional way to commence the year and an incredible opportunity for 4D to accelerate our mission. The speed of executing the teaming agreement, so rapidly after signing the MoU, is testament to the leadership commitment by the team at Philips North America, where their service to Veterans has been palpable throughout. The size and reach of Philips will dramatically accelerate the scaling of our offering within the VA. I am incredibly excited by the reach this will give our technology, and importantly, the impact this will have for millions of Veterans and their caregivers.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Chief Financial Officer
Simon Glover
sglover@4dmedical.com

Administration

Company Secretary
Naomi Lawrie
companysecretary@4dmedical.com

Media Enquiries

The Capital Network (TCN)
Julia Maguire
julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) - the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing clinical imaging equipment or the Company's revolutionary XV Scanner.



In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio's regulatory-cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity and more personalised care for patients.

To learn more, please visit www.4dmedical.com and www.imbio.com.

For personal use only